Alterity Therapeutics Limited (PBN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alterity Therapeutics Limited (PBN) has a cash flow conversion efficiency ratio of -0.222x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-5.06 Million ≈ $-5.91 Million USD) by net assets (€22.81 Million ≈ $26.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Alterity Therapeutics Limited - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Alterity Therapeutics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Alterity Therapeutics Limited for a breakdown of total debt and financial obligations.
Alterity Therapeutics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alterity Therapeutics Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
E& Corporation CO. LTD
KQ:066980
|
0.016x |
|
Zomedica Pharmaceuticals Corp
NYSE MKT:ZOM
|
-0.050x |
|
ONDINE BIOMEDICAL INC.CDI
F:VF5
|
N/A |
|
Wisekey International Holding AG
SW:WIHN
|
-0.118x |
|
Lokesh Machines Limited
NSE:LOKESHMACH
|
-0.077x |
|
Hotelim Société Anonyme
PA:MLHOT
|
N/A |
|
Havanna Holding SA
BA:HAVA
|
-0.059x |
|
Sajo Oyang
KO:006090
|
0.010x |
Annual Cash Flow Conversion Efficiency for Alterity Therapeutics Limited (2014–2025)
The table below shows the annual cash flow conversion efficiency of Alterity Therapeutics Limited from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Alterity Therapeutics Limited.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | €42.40 Million ≈ $49.57 Million |
€-11.45 Million ≈ $-13.39 Million |
-0.270x | +70.44% |
| 2024-06-30 | €13.80 Million ≈ $16.13 Million |
€-12.61 Million ≈ $-14.74 Million |
-0.914x | -4.02% |
| 2023-06-30 | €22.81 Million ≈ $26.67 Million |
€-20.04 Million ≈ $-23.42 Million |
-0.878x | -152.49% |
| 2022-06-30 | €35.47 Million ≈ $41.47 Million |
€-12.34 Million ≈ $-14.42 Million |
-0.348x | +38.84% |
| 2021-06-30 | €30.47 Million ≈ $35.62 Million |
€-17.33 Million ≈ $-20.26 Million |
-0.569x | +56.88% |
| 2020-06-30 | €7.15 Million ≈ $8.36 Million |
€-9.43 Million ≈ $-11.03 Million |
-1.319x | -56.46% |
| 2019-06-30 | €16.55 Million ≈ $19.35 Million |
€-13.95 Million ≈ $-16.31 Million |
-0.843x | -117.06% |
| 2018-06-30 | €16.08 Million ≈ $18.80 Million |
€-6.25 Million ≈ $-7.30 Million |
-0.388x | -56.86% |
| 2017-06-30 | €23.69 Million ≈ $27.70 Million |
€-5.87 Million ≈ $-6.86 Million |
-0.248x | -4.68% |
| 2016-06-30 | €31.37 Million ≈ $36.67 Million |
€-7.42 Million ≈ $-8.67 Million |
-0.237x | +14.91% |
| 2015-06-30 | €39.11 Million ≈ $45.73 Million |
€-10.87 Million ≈ $-12.71 Million |
-0.278x | +22.62% |
| 2014-06-30 | €37.69 Million ≈ $44.06 Million |
€-13.54 Million ≈ $-15.83 Million |
-0.359x | -- |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-… Read more